Answers are grounded in this paper and cite their sources.
Narrative review discusses structured evaluation and management of eosinophilia, highlighting etiologies and treatment options.
Eosinophilia is a heterogeneous clinical finding ranging from benign reactive states to clonal hematologic disorders associated with significant morbidity. This narrative, practical clinical review provides a structured, mechanism-based approach to the evaluation and management of peripheral eosinophilia by integrating contemporary consensus definitions, epidemiologic data, and diagnostic frameworks. Eosinophilia is defined as an absolute eosinophil count of ≥500 cells/µL, with hypereosinophilia defined as ≥1500 cells/µL. Etiologies are broadly classified as primary (clonal) or secondary (reactive). Peripheral eosinophil counts do not reliably predict organ involvement. Evaluation requires systematic assessment, including clinical history, laboratory testing, and targeted investigations. Management is guided by etiology and the presence of organ damage, with corticosteroids as first-line therapy in many cases and targeted therapies for clonal disease. The objective of this narrative, practical clinical review is to provide a structured, mechanism-based approach to the evaluation and management of peripheral eosinophilia, with emphasis on common reactive causes, recognition of organ involvement, and identification of high-risk clonal or hypereosinophilic presentations.
No takes yet. Share an insight, caveat, or question.
Ejaz Yousef (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: